
<div class="portfolio-view view">
	<div class="home-btn">
		<span>
			<img src="images/incyte-home-btn.png" alt="HOME" title="HOME">
		<span>
	</div>
	<div class="blue-text text-center">
			<h1>Incyte Portfolio</h1>
			<h3>(Touch each clinical trial for details.)</h3>
	</div>

<!--
	<div class="portfolio-key-box">
		<div style="position: relative;">
			<div class="key-boxes">
				<div></div>
				<div></div>
				<div></div>
				<br><br>
				<div></div>
				<div></div>
				<div></div>
				<br><br>
				<div></div>
				<div></div>
				<div></div>
			</div
>			<div class="key-boxes-text">
				<p>Incyte commercialization rights</p>
				<p>Global rights out-licensed</p>
				<p>European rights in-licensed</p>
			</div>
		</div>
	</div>
-->
<div class="container-fluid portfolio-wrapper">
	<div class="portfolio-top-nav">
		<ul>
			<li>DISCOVERY</li>
			<li>CLINICAL PROOF OF CONCEPT</li>
			<li>PIVOTAL</li>
			<li>MARKETED</li>
		</ul>
	</div>

	<div class="portfolio-lines">
	<span class="divider-line-one"></span>
	<span class="divider-line-one-bottom"></span>
	<span class="divider-line-two"></span>
	<span class="divider-line-two-bottom"></span>
	<span class="divider-line-three"></span>
	</div>
	<div class="targeted-therapies-container">
	<div class="row">
			<div class="col-xs-2">
					<h3>Targeted Therapy</h3>
			</div>

			<div class="col-xs-10">
				<div class="progress">
				  <div class="progress-bar width97" role="progressbar" aria-valuemax="95" style="width: 0%;" data-content="
				  &lt;h3&gt; Jakafi&lt;sup&gt;&reg;&lt;/sup&gt; (ruxolitinib) &lt;/h3&gt; 
				  &lt;a href='https://clinicaltrials.gov/ct2/show/NCT00952289?term=NCT00952289&rank=1' class='modal-show' &gt; &lt;b&gt; NCT00952289: &lt;/b&gt; Controlled MyeloFibrosis Study With Oral JAK Inhibitor Treatment: The COMFORT-I Trial&lt;/a&gt; 

				  &lt;a href='https://clinicaltrials.gov/ct2/show/NCT00934544?term=NCT00934544&rank=1' class='modal-show' &gt; &lt;b&gt; NCT00934544: &lt;/b&gt; Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial &lt;/a&gt;

				  &lt;a href='https://clinicaltrials.gov/ct2/show/NCT01243944?term=NCT01243944&rank=1' class='modal-show' &gt;  &lt;b&gt; NCT01243944: &lt;/b&gt; Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial) &lt;/a&gt;"
				  data-html="true">
							<ul>
								<li>Jakafi<sup>&reg;</sup> (ruxolitinib)<sup>1</sup></li>
								<li>JAK1/JAK2</li>
								<li>MF, PV<sup>2</sup></li>
								<li style="padding-left: 675px;">U.S.</li>
							</ul>
				
				  </div>

				</div>

				<div class="progress" >
					<div class="progress-bar width97" role="progressbar" aria-valuenow="75" aria-valuemin="0" aria-valuemax="90" style="width: 0%;" data-content="&lt;h3&gt; Iclusig&lt;sup&gt;&reg;&lt;/sup&gt; (ponatinib) &lt;/h3&gt; 
					&lt;a href='https://clinicaltrials.gov/ct2/show/NCT02627677?term=NCT02627677&rank=1' class='modal-show trigger-close' &gt; &lt;b&gt; NCT02627677: &lt;/b&gt; A Study Comparing Ponatinib and Nilotinib in Patients With Chronic Myeloid Leukemia (OPTIC&#8209;2L) &lt;/a&gt;"
					data-html="true">
							<ul>
								<li>Iclusig<sup>&reg;</sup> (ponatinib)<sup>3</sup></li>
								<li>BCR-ABL</li>
								<li>CML, Ph&#43;ALL</li>
								<li style="padding-left: 615px;">Europe</li>
							</ul>
					</div>
				</div>


 		<div class="progress">
			<div class="progress-bar width69" role="progressbar" aria-valuenow="75" aria-valuemin="0" aria-valuemax="90" style="width: 0%;" data-content="&lt;h3&gt; Iclusig&lt;sup&gt;&reg;&lt;/sup&gt; (ponatinib) &lt;/h3&gt; 
					&lt;a href='http://www.businesswire.com/news/home/20160623005540/en/FDA-Grants-Breakthrough-Therapy-Designation-Incyte%E2%80%99s-Ruxolitinib' class='modal-show trigger-close' &gt; &lt;b&gt; NCT02627677: &lt;/b&gt; Press Release: FDA Grants Breakthrough Therapy Designation for Incyte’s Ruxolitinib (Jakafi®) in Acute Graft-Versus-Host Disease (GVHD) &lt;/a&gt;" data-html="true">
						<ul>
							<li>Ruxolitinib<sup>4</sup></li>
							<li>JAK1/JAK2</li>
							<li>GVHD</li>
						</ul>			
			</div>
		</div>

				<div class="progress">
					<div class="progress-bar" role="progressbar" aria-valuenow="75" aria-valuemin="0" aria-valuemax="90" style="width: 0%;" data-content="&lt;h3&gt; INCB39110 &lt;/h3&gt; 
				  &lt;a href='https://clinicaltrials.gov/ct2/show/NCT02614612?term=NCT02614612&rank=1' class='modal-show' &gt; &lt;b&gt; NCT02614612: &lt;/b&gt; Study of INCB039110 in Combination With Corticosteroids for the Treatment of Acute GVHD&lt;/a&gt; 

				  &lt;a href='https://clinicaltrials.gov/ct2/show/NCT02917993?term=incb039110&rank=6' class='modal-show' &gt; &lt;b&gt; NCT02917993: &lt;/b&gt; An Open-Label Phase 1/2 Study of INCB039110 in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer &lt;/a&gt;"

				   data-html="true">
							<ul>
								<li>INCB39110</li>
								<li>JAK1</li>
								<li>GVHD, NSCLC</li>
							</ul>
					</div>
				</div>
				<div class="progress">
					<div class="progress-bar" role="progressbar" aria-valuenow="75" aria-valuemin="0" aria-valuemax="90" style="width: 0%;" data-content="&lt;h3&gt; INCB52793 &lt;/h3&gt; &lt;a href='https://clinicaltrials.gov/ct2/show/NCT02265510?term=NCT02265510&rank=1' class='modal-show trigger-close' &gt; &lt;b&gt; NCT02265510: &lt;/b&gt; An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies &lt;/a&gt;" data-html="true">
							<ul>
								<li>INCB52793</li>
								<li>JAK1</li>
								<li>Advanced malignancies</li>
							</ul>
					</div>
				</div>

				<div class="progress">
					<div class="progress-bar" role="progressbar" aria-valuenow="75" aria-valuemin="0" aria-valuemax="90" style="width: 0%;" data-content="&lt;h3&gt; INCB50465 &lt;/h3&gt; &lt;a href='https://clinicaltrials.gov/ct2/show/NCT02018861?term=NCT02018861&rank=1' class='modal-show' &gt; &lt;b&gt; NCT02018861: &lt;/b&gt; A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and INCB039110 in Subjects With Previously Treated B-Cell Malignancies &lt;/a&gt;
					                                  
					&lt;a href='https://clinicaltrials.gov/ct2/show/NCT02718300?term=NCT02718300&rank=1' class='modal-show' &gt; &lt;b&gt; NCT02718300: &lt;/b&gt; A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis &lt;/a&gt;" 

					data-html="true">
							<ul>
								<li>INCB50465</li>
								<li>PI3K&delta;</li>
								<li>Hematological malignancies</li>
							</ul>
					</div>
				</div>
				<div class="progress">
					<div class="progress-bar" role="progressbar" aria-valuenow="75" aria-valuemin="0" aria-valuemax="90" style="width: 0%;" data-content="&lt;h3&gt; INCB54828 &lt;/h3&gt; &lt;a href='https://clinicaltrials.gov/ct2/show/NCT02872714?term=NCT02872714&rank=1' class='modal-show' &gt; &lt;b&gt; NCT02872714: &lt;/b&gt; A Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Urothelial Carcinoma &lt;/a&gt;

					&lt;a href='https://clinicaltrials.gov/ct2/show/NCT02924376?term=INCB054828&rank=1' class='modal-show' &gt; &lt;b&gt; NCT02924376: &lt;/b&gt; Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy &lt;/a&gt;

					&lt;a href='https://clinicaltrials.gov/ct2/show/NCT02393248?term=NCT02393248&rank=1' class='modal-show' &gt; &lt;b&gt; NCT02393248: &lt;/b&gt; Open-Label, Dose-Escalation Study of INCB054828 in Subjects With Advanced Malignancies &lt;/a&gt;" 

					data-html="true">
							<ul>
								<li>INCB54828</li>
								<li>FGFR</li>
								<li>Bladder cancer, cholangiocarcinoma</li>
							</ul>						
					</div>
				</div>
				<div class="progress">
					<div class="progress-bar" role="progressbar" aria-valuenow="75" aria-valuemin="0" aria-valuemax="90" style="width: 0%;" data-content="&lt;h3&gt; INCB54329 &lt;/h3&gt; &lt;a href='https://clinicaltrials.gov/ct2/show/NCT02431260?term=NCT02431260&rank=1' class='modal-show trigger-close' &gt; &lt;b&gt; NCT02431260: &lt;/b&gt; An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies &lt;/a&gt;" data-html="true">
							<ul>
								<li>INCB54329</li>
								<li>BRD</li>
								<li>Advanced malignancies</li>
							</ul>
					</div>
				</div>

				<div class="progress">
					<div class="progress-bar" role="progressbar" aria-valuenow="75" aria-valuemin="0" aria-valuemax="90" style="width: 0%;" data-content="&lt;h3&gt; INCB57643 &lt;/h3&gt; &lt;a href='https://clinicaltrials.gov/ct2/show/NCT02711137?term=INCB057643&rank=1' class='modal-show trigger-close' &gt; &lt;b&gt; NCT02711137: &lt;/b&gt; A Phase 1/2, Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies &lt;/a&gt;" data-html="true">
							<ul>
								<li>INCB57643</li>
								<li>BRD</li>
								<li>Advanced malignancies</li>
							</ul>
					</div>
				</div>

				<div class="progress">
					<div class="progress-bar" role="progressbar" aria-valuenow="75" aria-valuemin="0" aria-valuemax="90" style="width: 0%;" data-content="&lt;h3&gt; INCB53914 &lt;/h3&gt; &lt;a href='https://clinicaltrials.gov/ct2/show/NCT02587598?term=NCT02587598&rank=1' class='modal-show trigger-close' &gt; &lt;b&gt; NCT02587598: &lt;/b&gt; Study of INCB053914 in Subjects With Advanced Malignancies &lt;/a&gt;" data-html="true">
							<ul>
								<li>INCB53914</li>
								<li>PIM</li>
								<li>Advanced malignancies</li>
							</ul>						
					</div>
				</div>
				<div class="progress">
					<div class="progress-bar width42" role="progressbar" aria-valuenow="75" aria-valuemin="0" aria-valuemax="90" style="width: 0%;" data-content="&lt;h3&gt; INCB59872 &lt;/h3&gt; &lt;a href='https://clinicaltrials.gov/ct2/show/NCT02712905?term=NCT02712905&rank=1' class='modal-show trigger-close' &gt; &lt;b&gt; NCT02712905: &lt;/b&gt; An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies &lt;/a&gt;" data-html="true">
							<ul>
								<li>INCB59872</li>
								<li>LSD1</li>
								<li>AML, small cell lung cancer</li>
							</ul>
					</div>
				</div>
			</div><!-- /col-lg-10 -->
		</div><!-- /row -->
	</div><!-- /targeted-therapies-container -->

	<div class="immuno-therapies-container">
		<div class="row">
				<div class="col-xs-2">
						<h3>Immuno-<br>Therapy</h3>
				</div>

				<div class="col-xs-10">
		<div class="progress">
		  <div class="progress-bar width72 removeStyle" role="progressbar" aria-valuemax="95" style="width: 0%;" data-content="
			&lt;span class='portofolio-purple'&gt; 
		  &lt;h3&gt;Epacadostat &lt;/h3&gt; &lt;a href='https://clinicaltrials.gov/ct2/show/NCT02752074?term=NCT02752074&rank=1' class='modal-show trigger-close' &gt; &lt;b&gt; NCT02752074: &lt;/b&gt; A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma &lt;/a&gt;
			&lt;/span&gt;"
		  data-html="true">
						<ul>
							<li>Epacadostat</li>
							<li>IDO1</li>
							<li>Melanoma</li>
						</ul>
		  </div>
		</div>

		<div class="progress">
			<div class="progress-bar width66" role="progressbar" aria-valuenow="75" aria-valuemin="0" aria-valuemax="90" style="width: 0%;" data-content="&lt;span class='portofolio-purple'&gt; 
 					&lt;h3&gt; Epacadostat &lt;/h3&gt; &lt;a href='https://clinicaltrials.gov/ct2/show/NCT02318277?term=A+Study+of+Epacadostat+%28INCB024360%29+in+Combination+With+Durvalumab+%28MEDI4736%29+in+Subjects+With+Selected+Advanced+Solid+Tumors+%28INCB+24360-203+%2F+ECHO-203%29&rank=1' class='modal-show' &gt; &lt;b&gt; NCT02318277: &lt;/b&gt; A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (INCB 24360-203 / ECHO-203) &lt;/a&gt;
			
				  &lt;a href='https://clinicaltrials.gov/ct2/show/NCT02298153?term=A+Study+of+Atezolizumab+%28MPDL3280A%29+in+Combination+With+Epacadostat+%28INCB024360%29+in+Subjects+With+Previously+Treated+Stage+IIIB+or+Stage+IV+Non-Small+Cell+Lung+Cancer+and+Previously+Treated+Stag' class='modal-show' &gt; &lt;b&gt; NCT02298153: &lt;/b&gt; A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (INCB 24360-110 / ECHO-110) &lt;/a&gt;

				  &lt;a href='A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)' class='modal-show' &gt; &lt;b&gt; NCT02327078: &lt;/b&gt; A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers &lt;/a&gt;

				  &lt;a href='https://clinicaltrials.gov/ct2/show/NCT02178722?term=NCT02178722&rank=1' class='modal-show' &gt; &lt;b&gt; NCT02178722: &lt;/b&gt; A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (INCB 24360-202 / MK-3475-037 / KEYNOTE-037/ ECHO-202) &lt;/a&gt;

				  &lt;a href='https://clinicaltrials.gov/ct2/show/NCT02559492?term=INCB050465&rank=3' class='modal-show' &gt; &lt;b&gt; NCT02559492: &lt;/b&gt; INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors &lt;/a&gt;
		        	&lt;/span&gt;"
				  data-html="true">
						<ul>
							<li>Epacadostat</a></li>
							<li>IDO1</li>
							<li>Multiple tumor types</li>
						</ul>
			</div>
		</div>
		<div class="progress">
			<div class="progress-bar width42" role="progressbar" aria-valuenow="75" aria-valuemin="0" aria-valuemax="90" style="width: 0%;" data-content="&lt;span class='portofolio-purple'&gt; 
 &lt;h3&gt; INCSHR1210 &lt;/h3&gt; &lt;a href='https://clinicaltrials.gov/ct2/show/NCT02492789?term=NCT02492789&rank=1' class='modal-show trigger-close' &gt; &lt;b&gt; NCT02492789: &lt;/b&gt; A Trial to Evaluate Safety and Tolerability of SHR-1210 in Cancer Patients &lt;/a&gt; &lt;/span&gt;" data-html="true">
						<ul>
							<li>INCSHR1210</li>
							<li>PD-1</li>
							<li>Solid tumors</li>
						</ul>			
			</div>
		</div>

		<div class="progress">
			<div class="progress-bar width42" role="progressbar" aria-valuenow="75" aria-valuemin="0" aria-valuemax="90" style="width: 0%;" data-content="&lt;span class='portofolio-purple'&gt;  &lt;h3&gt; INCAGN1876 &lt;/h3&gt; &lt;a href='https://clinicaltrials.gov/ct2/show/NCT02697591?term=NCT02697591&rank=1' class='modal-show trigger-close' &gt; &lt;b&gt; NCT02697591: &lt;/b&gt; An Open-Label, Dose-Escalation, Safety Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors &lt;/a&gt; &lt;/span&gt;" data-html="true">
						<ul>
							<li>INCAGN1876<sup>5</sup></li>
							<li>GITR</li>
							<li>Solid tumors</li>
						</ul>
			</div>
		</div>
		<div class="progress">
			<div class="progress-bar width34" role="progressbar" aria-valuenow="75" aria-valuemin="0" aria-valuemax="90" style="width: 0%;" data-content="&lt;span class='portofolio-purple'&gt; &lt;h3&gt; NCT02923349 &lt;/h3&gt; &lt;a href='https://clinicaltrials.gov/ct2/show/NCT02923349?term=nct02923349&rank=1' class='modal-show trigger-close' &gt; &lt;b&gt; NCT02697591: &lt;/b&gt; A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors &lt;/a&gt; &lt;/span&gt;" data-html="true">
						<ul>
							<li>INCAGN1949<sup>5</sup></li>
							<li>OX40</li>
							<li>Solid tumors</li>
						</ul>			
			</div>
		</div>
		</div><!-- /col-lg-10 -->
	</div><!-- /row -->
</div><!-- /immuno-therapies-container -->


<div class="non-oncology-container">
		<div class="row">
		<div class="col-xs-2">
				<h3>Non-Onc</h3>
		</div>

		<div class="col-xs-10">

						<div class="progress">
					<div class="progress-bar width54" role="progressbar" aria-valuenow="75" aria-valuemin="0" aria-valuemax="90" style="width: 0%;" data-content="&lt;span class='portofolio-redish'&gt;  &lt;h3&gt; Topical ruxolitinib &lt;/h3&gt; &lt;a href='https://clinicaltrials.gov/ct2/show/NCT02553330?term=NCT02553330&rank=1' class='modal-show trigger-close' &gt; &lt;b&gt; NCT02553330: &lt;/b&gt; A Study With INCB018424 Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA) &lt;/a&gt;  &lt;/span&gt;" data-html="true">
								<ul>
									<li>Topical ruxolitinib</li>
									<li>JAK1/JAK2</li>
									<li>Alopecia areata</li>
								</ul>			
					</div>
				</div>

		</div><!-- /col-lg-10 -->
	</div><!-- /row -->
</div><!-- /non-oncology-container -->

<div class="partnered-container">
		<div class="row">
		<div class="col-xs-2">
				<h3>Partnered</h3>
		</div>

		<div class="col-xs-10">
		<div class="progress">
		  <div class="progress-bar width81 partnered-color" role="progressbar" aria-valuemax="95" aria-valuemin="0" aria-valuemax="90" style="width: 0%;" data-content="&lt;span class='portofolio-blue'&gt; 
 &lt;h3&gt; Baricitinib &lt;/h3&gt;  &lt;a href='http://www.incyte.com/' class='modal-show trigger-close' &gt; For information on clinical trials in rheumatoid arthritis with baricitinib, please visit Incyte.com &lt;/a&gt; &lt;/span&gt;"
 data-html="true">
						<ul>
							<li>Baricitinib<sup>6</sup></li>
							<li>JAK1/JAK2</li>
							<li>Rheumatoid arthritis</li>
						</ul>
		  </div>
		</div>

		<div class="progress">
			<div class="progress-bar width54 partnered-color" role="progressbar" aria-valuenow="75" aria-valuemin="0" aria-valuemax="90" style="width: 0%;" data-content="&lt;span class='portofolio-blue'&gt; 
 &lt;h3&gt; Baricitinib &lt;/h3&gt; &lt;a href='http://www.incyte.com/' class='modal-show trigger-close' &gt; For information on clinical trials in atopic dermatitis and systemic lupus erythematosus (SLE) with baricitinib, please visit Incyte.com &lt;/a&gt;       &lt;/span&gt;"
data-html="true">
						<ul>
							<li>Baricitinib<sup>6</sup></li>
							<li>JAK1/JAK2</li>
							<li>Atopic dermatitis, SLE</li>
						</ul>
			</div>
		</div>

				<div class="progress" >
					<div class="progress-bar width66 partnered-color" role="progressbar" aria-valuenow="75" aria-valuemin="0" aria-valuemax="90" style="width: 0%;" data-content="&lt;span class='portofolio-blue'&gt; 
 &lt;h3&gt; Capmatinib &lt;/h3&gt; &lt;a href='http://www.incyte.com/' class='modal-show trigger-close' &gt; For information on clinical trials in non-small cell lung cancer (NSCLC), glioblastoma multiforme (GBM) and liver cancer with capmatinib, please visit Incyte.com &lt;/a&gt; &lt;/span&gt;" data-html="true">
							<ul>
								<li>Capmatinib<sup>7</sup></li>
								<li>c-MET</li>
								<li>NSCLC, liver cancer, GBM</li>
							</ul>
					</div>
				</div>
		</div><!-- /col-lg-10 -->
	</div><!-- /row -->
</div><!-- /non-oncology-container -->


	<div class="footnotesSS">
			<div class="col-xs-12">
				<strong>1. </strong> Jakafi marketed by Incyte in the US; ruxolitinib licensed to Novartis ex-US <strong>2. </strong> Patients with intermediate or high-risk myelofibrosis; Patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea <span class="nowrap"><strong>3. </strong>European rights</span> to Iclusig licensed from ARIAD <strong>4.</strong> Registration trial expected to begin in H2 2016 <strong>5. </strong> Co-development with Agenus <strong>6. </strong> Worldwide rights to baricitinib licensed to Lilly, SLE = Systemic lupus erythematosus <span class="nowrap"><strong>7. </strong> Worldwide rights</span> to capmatinib licensed to Novartis, GBM = Glioblastoma multiforme
			</div>
<!-- 	 	<div class="col-xs-6">
	 		<ol>
	 			<li>Jakafi marketed by Incyte in the US; ruxolitinib licensed to Novartis ex-US</li>
	 			<li>Patients with intermediate or high-risk myelofibrosis; Patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea</li>
	 			<li>European rights to Iclusig licensed from ARIAD</li>
	 		</ol>
	 	</div>
	 	<div class="col-xs-6">
	 		<ol start="4">
	 			<li>Worldwide rights to capmatinib licensed to Novartis, GBM = Glioblastoma multiforme</li>
	 			<li>Co-development with Agenus</li>
	 			<li>Worldwide rights to baricitinib licensed to Lilly, AtD = Atopic dermatitis, SLE = Systemic lupus erythematosus</li>
	 			<li>Registration trial expected to begin in H2 2016</li>
	 		</ol>
	 	</div> -->
	</div>
</div>
</div>

<!-- NAVIGATION -->
<!-- <aside class="side-nav"></aside>
 -->
<div class="popover-bg"><img class="popover-close" src="images/close-btn.png" alt="Close"><div class="data-content-html"></div></div>

